Durham (NC, USA) and Liege (Belgium) - June 22, 2010, 18:00 CET - OncoMethylome Sciences SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA) reports that as of June 14, 2010, ING Investment Management Luxembourg SA's shareholding is 4.95% of the total 13,185,614 outstanding shares of the company.
For further details on the transparency notifications received by the company, reference is made to our website www.oncomethylome.com.
About OncoMethylome Sciences
OncoMethylome Sciences is a leading molecular diagnostics company that commercializes and develops cancer-screening tests to assist physicians in detecting and treating cancer early. The company's tests are based on proprietary gene methylation technology invented at Johns Hopkins University and are designed to help the physician accurately detect early stages of cancer development, predict a patient's response to drug therapy, and predict the likelihood of cancer recurrence. OncoMethylome Sciences collaborates with leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and has a number of commercial and collaborative partnerships with LabCorp, Schering-Plough, GlaxoSmithKline Biologicals, Millipore Corporation's BioScience Division, Roche, Merck KGaA and Qiagen.
For more information:
Philip Devine (DECOFI SPRL)
CFO
+32 4.364.20.70 office
IR@oncomethylome.com
